Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This dissertation found that finasteride reduced prostate volume by 6.3% and total serum PSA by 10.51% in young patients over one year.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

This study found that a 3 mm margin around the prostate CTV may be adequate if accompanied by frequent imaging, but superior-inferior displacements were notably greater than in other directions.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This review discusses the expanding understanding of TRPV3's role in pain and skin pathology, while highlighting the need for further pharmacological research to fully resolve its functions.

This report discusses a case of pediatric trichotillomania, detailing its clinical presentation and distinguishing histopathological characteristics, ultimately diagnosing the condition in a 7-year-old boy with nonscarring alopecia.

This review discusses the potential benefits of pumpkin seed oil for men's health, particularly in conditions such as benign prostatic hyperplasia, overactive bladder, and androgenic alopecia, but reports no new clinical results.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

In this case study, researchers observed that steroidogenesis from adrenal androgens in prostate cancer tissues may explain progression in a 74-year-old man with low circulating testosterone.

This case-control study found no significant link between androgenic alopecia or hypertrichosis and prostate cancer in Dravidian men from Tamil Nadu, suggesting different prostate cancer risk factors compared to Western populations.

The EPICAP study aims to investigate various factors influencing prostate cancer, including circadian disruption, inflammation, hormonal and metabolic factors, and genetic susceptibility, and reports no new clinical results.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This review explores the potential impact of hormonal changes during aging on benign prostate hyperplasia-related urinary symptoms and metabolic syndrome, highlighting the hypothesis of a male PCOS-equivalent but reports no new clinical results.

This review discusses managing prostate cancer in patients with high-risk germline mutations and highlights the need for more research and consensus guidelines, reporting no new clinical results.

This paper identifies challenges in diagnosing alopecia variants, emphasizing the importance of pathologists understanding hair follicle histology, biopsy types, and collaborating with dermatologists to improve diagnostic accuracy.

This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This review summarizes recent research on the molecular properties and functions of L-PGDS and PGD2, but reports no new findings, highlighting their pathophysiological roles and guiding future studies.

This study reported that solid lipid nanoparticles of finasteride decorated with chitosan enhanced drug retention in skin layers, suggesting potential application in treating androgenic alopecia and benign prostate hyperplasia with fewer side effects.

This study presents the crystal structure of human SRD5A2 with finasteride and reveals insights into its enzyme catalysis and inhibition mechanisms, which may inform drug development.

Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.

Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.

In this study, finasteride alone or combined with terazosin significantly reduced PSA levels in men with BPH, while terazosin alone did not affect PSA levels.

This study found no relationship between androgenic alopecia and parameters such as PSA level, IPSS, and prostate volume in men over 50.

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

This document outlines recommendations from an international panel on testosterone therapy for aging men with late-onset hypogonadism, emphasizing the need for careful assessment and monitoring due to limited long-term safety data.